門診處方討論門診處方討論 Thalidomide 用於癌症的治療報告者 : 邱英滋藥師 95.04.24.

Slides:

Advertisements

Similar presentations

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Advertisements

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

Robertson JFR et al. J Clin Oncol 2009;27(27):

Palumbo A et al. Proc ASH 2012;Abstract 446.

Ibrance® - Palbociclib

門診處方用藥討論報告日期：報告者：張美琪藥師 Methylphenidate(Ritalin) for the treatment of Attention deficit hyperactivity disorder.

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Successful treatment of pediatric desmoid tumors using hydroxyurea Naomi Balamuth, M.D. Richard Womer, M.D. November 13, 2008.

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

LEVAMISOLE 於牙科的使用傅任巧藥劑科 Levamisole 藥理生理學 immunomodulatory activity T-cell activity and to have enhancing effects on the functions of.

Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.

1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.

Birth defects caused by use of thalidomide Example: Thalidomide From 1956 to 1962, approximately 10,000 children were born with severe malformities,

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

門診處方討論 - Colchicine for Recurrent aphthous stomatitis(RAS) 報告日期 : 報告日期 : 報告人 : 黃梁灝藥師報告人 : 黃梁灝藥師.

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

Palumbo A et al. Proc ASH 2014;Abstract 175.

High-dose progestins for the treatment of cancer anorexia - cachexia syndrome 主講人 : 徐嫈惠 2008/01/29.

Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

門診處方討論 Nifedipine 用於安胎主講者 : 黃意文. Nifedipine ❃ OVERVIEW A. Nifedipine is a calcium channel antagonist. B. Nifedipine is a vasodilator with antianginal.

Treon SP et al. Proc ASH 2013;Abstract 251.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Locatelli F et al. Proc ASH 2013;Abstract 4378.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

1 門診處方討論 Nadolol 用於 Gastrointestinal tract bleeding 的治療報告者：蔡岱利

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) second interim analysis in.

SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.

Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.

門診處方討論報告日期 : 報告者 : 王士昇藥師. Sulfamethoxazole+Trimethoprim(Baktar) 在後天免疫不全症候群患者之應用 Pneumocystis carinii Pneumonia (PCP) 常發生於 HIV 感染的患者 Baktar.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Lenalidomide plus dexamethasone is more effective than dexamethasone alone inpatients with relapsed or refractory multiple myeloma regardless of prior.

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.

Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.

ESMO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR

在使用Sorafenib治療肝細胞癌過程中患有

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.

Korde N et al. Proc ASH 2012;Abstract 732.

Gajria D et al. Proc SABCS 2010;Abstract P

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*

A REVIEW AND UPDATE ON THE ANTI-ANGIOGENIC AGENT, ABT-510

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

CCO Independent Conference Coverage

Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.

Intervista a Lucio Crinò

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Barrios C et al. SABCS 2009;Abstract 46.

Bergh J et al. SABCS 2009;Abstract 23.

Martin M et al. Proc SABCS 2012;Abstract S1-7.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Presentation transcript:

門診處方討論門診處方討論 Thalidomide 用於癌症的治療報告者 : 邱英滋藥師

Thalidomide 之 Clinical Applications FDA Approved Indications  Erythema Nodosum Leprosum (ENL) use dose ： mg/day Therapeutic use  Cancer (Hepatocellular carcinoma,Multiple myeloma, Prostate cancer, Breast cancer,Renal cell carcinoma......) use dose ： mg/day

Thalidomide 於 cancer 治療之機轉 Exact mechanism by which thalidomide produces beneficial effects in cancer patients is unknown, several proposed mechanisms exist: 1) thalidomide may inhibit growth and survival of myeloma cells by oxidative damage to DNA mediated by free radicals. (Hideshima et al, 2000)

Thalidomide–DNA intercalation

Thalidomide 於 cancer 治療之機轉 2) may alter the secretion and biologic activity of cytokines (eg, interleukin-6, 1- beta, and 10, tumor necrosis factor). 3) may reduce angiogenesis by inhibiting vascular endothelial growth factor and basic fibroblast growth factor 2. (Raje & Anderson, 1999a) 4) antiinflammatory and immunemodulatory

服藥期間： 1/11-3/10

Thalidomide 於 Hepatocellular carcinoma 治療之臨床證據 (1) 於間罹患 Hepatocellular carcinoma(HCC) 的 37 位病患給予 thalidomide ，劑量由 400mg/day( 第一週 ) 慢慢增加至 1000mg/day( 第五週 ) ， BID 給藥，持續 8 週。 Reference: Patt YZ. Hassan MM. Lozano RD. Nooka AK. Schnirer II. Zeldis JB. Abbruzzese JL. Brown TD. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 103(4):749-55, 2005 Feb 15.

Thalidomide 於 Hepatocellular carcinoma 治療之臨床證據 (1) With a 5% PR rate, a 5% MR rate, and a 31% SD rate (95% confidence interval [95%CI], %), and 20 patients(61%; 95%CI, 42-78%) had disease progression.The overall median survival was 6.8 months. The results indicate that thalidomide mostly may offer HCC patients disease stabilization.

Thalidomide 於 Hepatocellular carcinoma 治療之臨床證據 (1) In fact, only 48% of patients tolerated a daily dose > 800 mg if it was delivered at bedtime. In view of the significant neurologic toxicity, thalidomide monotherapy at the high doses studied cannot be recommended for the treatment of HCC.

Thalidomide 於 Hepatocellular carcinoma 治療之臨床證據 (2) Sixty-eight patients with unresectable and nonembolizable HCC in a compassionate treatment program of oral thalidomide. Tumor response and treatment-related toxicity were prospectively followed. Thalidomide was given at a starting dose of 200 mg per day. The dose was gradually escalated in 100- mg steps up to 600 mg per day if no limiting toxicities developed. Reference: Chiun Hsua, Chiung-Nien Chen, Li-Tzong Chen, Chen-Yao Wu, Pei-Ming Yang, Ming- Yang Lai, Po-Huang Lee, Ann-Lii Cheng. Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma. Oncology 2003;65:

Thalidomide 於 Hepatocellular carcinoma 治療之臨床證據 (2) Sixty-three patients were evaluable for response. The duration of response was 50+, 24.6, and 8.7+ weeks, respectively. All 4 responders had a dramatic decrease in α -fetoprotein ( α -FP) levels. The median overall survival for all of the 68 patients was 18.7 weeks (95% CI ) with a 1-year survival rate of 27.6%.

Thalidomide 於 Hepatocellular carcinoma 治療之臨床證據 (2) All responders responded at a dose equal to or less than 300 mg per day. Toxicities of thalidomide were generally manageable, and only 16, 6, and 0 patients developed grade 2, 3, and 4 toxicities, respectively. Conclusion: Low-dose thalidomide is safe and induces unequivocal tumor response in a minority of patients with advanced HCC.

Thalidomide 之 Adverse Reactions Teratogenicity Neurologic neuropathy somnolence Edema 、 constipation 、 fatigue 、 nausea

Thalidomide 於 cancer 之結論 FDA Approval: Adult, no; Pediatric, no Efficacy: Adult, Evidence is inconclusive Recommendation: Adult, Class III Strength of Evidence: Adult, Category B Referevence: Micromedex

References  MICROMEDEX  Patt YZ. Hassan MM. Lozano RD. Nooka AK. Schnirer II. Zeldis JB. Abbruzzese JL. Brown TD. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 103(4):749-55, 2005 Feb 15.  Chiun Hsua, Chiung-Nien Chen, Li-Tzong Chen, Chen-Yao Wu, Pei-Ming Yang, Ming-Yang Lai, Po-Huang Lee, Ann-Lii Cheng. Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma. Oncology 2003;65: